Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [3] Core Insights - The recent policy released by the Ministry of Commerce and eight other departments aims to promote high-quality development in the pharmaceutical retail industry, which is expected to accelerate industry consolidation and benefit leading companies [6][28] - The pharmaceutical retail sector is anticipated to see improved performance expectations due to favorable policies, with a recommendation to focus on quality pharmacy enterprises such as Yifeng Pharmacy and Dazhenglin [6][33] Market Performance - The pharmaceutical and biotechnology index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th in industry performance [11] - Year-to-date, the pharmaceutical and biotechnology index has increased by 6.66%, outperforming the CSI 300 index by 5.1 percentage points, ranking 16th [11] - The best-performing sub-sector this week was pharmaceutical commerce, which rose by 4.26%, while chemical pharmaceuticals fell by 1.11% [17] Stock Performance - Among 478 pharmaceutical and biotechnology stocks, 338 stocks increased, representing 70.71% of the total [22] - The top five A-share stocks by performance this week were: *ST Changyao (+70.37%), Hualan Biological Engineering (+32.21%), Kangzhong Medical (+25.47%), Hanshang Group (+20.06%), and Wanze Shares (+19.04%) [22] - In the Hong Kong market, 116 pharmaceutical and biotechnology stocks saw 32 stocks rise, accounting for 27.59% [25] Industry News and Policies - The Ministry of Commerce and other departments released an opinion on promoting high-quality development in the pharmaceutical retail industry, proposing 18 specific measures to enhance service quality and optimize industry structure [28] - The FDA granted fast-track designation to CM336, a dual antibody developed by Kangnuo, for the treatment of autoimmune hemolytic anemia and immune thrombocytopenia [31] Recommendations - The report suggests focusing on quality pharmacy enterprises in light of the favorable policies for the pharmaceutical retail sector [33] - It also highlights the potential for vaccine companies in response to the recent Nipah virus cases in India, recommending attention to companies like Zhifei Biological, Kangtai Biological, Watson Bio, and CanSino [34]

智通财经APP获悉，随着今年并购交易活动强势启动，矿业巨头嘉能可在并购专家眼中成为2026年最有 可能被收购的欧洲企业。在媒体本月对30家风险套利交易台、交易员和分析师进行的一项非正式调查 中，正在与力拓(RIO.US)洽谈合并、以打造全球最大矿业公司的嘉能可被提及8次。 此外，调查结果显示，来自广泛行业的公司纷纷上榜，反映出随着全球经济动能增强，潜在收购方正将 目光投向更广阔的领域。法国生物科技公司Abivax SA被提及5次。该公司股价在2025年因潜在收购前景 以及积极的药物试验结果而暴涨逾1600%。英国石油(BP.US)、德国在线外卖订餐服务平台Delivery Hero SE、英国廉价航空公司EasyJet Plc和英国老牌房地产开发商Great Portland Estates则各被提及4次。 受访者还表示，全球并购环境正变得日益活跃。数据显示，今年以来截至1月23日，全球已宣布的并购 交易总额已超过630亿美元，是2025年同期记录金额的三倍以上。Neuberger Berman首席策略组负责人 约瑟夫·罗特表示："并购交易量尚处于回升的初期阶段。相比以往几年更偏向特定行业，如今的前景似 乎正 ...

Core Viewpoint - Ruian Gene (688217.SH) faces dual setbacks as its actual controllers are sued for fraud, and the company forecasts a significant revenue drop for 2025, indicating a severe decline in financial performance and trust [2][10]. Group 1: Company Background - Ruian Gene was founded by actual controllers Xiong Hui and Xiong Jun, who have impressive academic backgrounds and initially developed a clinical HBV drug resistance testing kit, filling a technological gap in the market [5]. - The company went public on the STAR Market in May 2021, becoming a star in precision medicine due to its technological advantages in leukemia detection, with the controlling family holding over 30% of the shares [5][6]. Group 2: Fraud Allegations and Investigation - The fraud investigation began in July 2021 when the Shenzhen Medical Insurance Bureau received reports of employees from AstraZeneca allegedly altering cancer patient gene test results to fraudulently obtain insurance reimbursements [6][9]. - Ruian Gene was implicated as a key player in the fraud chain, with its subsidiary Wuhan Sitai being mentioned in court proceedings regarding the manipulation of test results [9][10]. Group 3: Financial Performance and Forecast - The company forecasts a revenue of only 170 million to 176 million yuan for 2025, representing a year-on-year decline of 27.36% to 29.84%, with net losses expected to widen to between 39.91 million and 59.86 million yuan [2][12]. - The core business of molecular diagnostic reagent sales has been severely impacted, with a nearly 20% decline in revenue in the first half of 2025, and the testing service business experiencing a 30.2% drop in revenue [13][15]. Group 4: Governance and Management Response - Following the legal troubles of the actual controllers, the company's governance structure has not changed significantly, with Xiong Hui resigning from her positions in September 2025 but her husband quickly taking over [10][18]. - Despite ongoing financial losses and the legal issues, the company approved a cash dividend of 1.7 yuan per 10 shares, reflecting a disconnect between management decisions and financial realities [17][18]. Group 5: Industry Implications - The situation at Ruian Gene serves as a cautionary tale for the precision medicine industry, emphasizing the importance of trust and integrity in maintaining market position and customer relationships [20].

Core Insights - The JPMorgan Global Healthcare Conference serves as a significant platform for the biopharmaceutical industry, influencing capital flows and industry dynamics for the year ahead [1] - This year's conference highlighted the increasing presence of Chinese biotech companies, marking a shift from being mere spectators to key players in the global market [2][3] Group 1: Chinese Biotech Companies - Seven Chinese companies, including WuXi AppTec and BeiGene, presented on the main stage, with an additional 17 companies showcasing in the Asia-Pacific session [2] - The transformation of Chinese companies from the periphery to the center of the conference reflects their substantial innovation value, evidenced by numerous licensing deals announced during the event [3] Group 2: Licensing Deals and Collaborations - Notable licensing agreements included a $650 million upfront payment from AbbVie to Rongchang Biopharma for the global rights to its PD-1/VEGF dual-specific antibody, with a total potential deal value of up to $5.6 billion [3] - Other significant collaborations involved Zhongsheng Peptide and Sai Shen Pharmaceutical partnering with Novartis, with the latter's deal valued at approximately $1.665 billion [3] Group 3: MNCs and Market Dynamics - The cautious approach of multinational corporations (MNCs) towards acquisitions is driven by the impending "patent cliff," with over $320 billion in market potential products set to lose patent protection in the next decade [3][5] - MNCs are increasingly favoring "asset-based acquisitions" over full company buyouts, allowing them to efficiently acquire core assets without the burdens of integrating entire companies [4] Group 4: AI in Drug Development - AI's integration into drug development emerged as a central theme, with Eli Lilly and NVIDIA announcing a partnership to establish a $1 billion AI innovation lab aimed at addressing long-standing challenges in the pharmaceutical industry [5][6] - The acquisition of Modella AI by AstraZeneca further emphasizes the growing importance of AI in enhancing drug discovery and clinical development processes [6] Group 5: Future Outlook - The 2026 JPM conference is expected to reflect a new paradigm where Chinese innovation becomes essential, and AI evolves from a supportive tool to a foundational infrastructure in drug development [8][9]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 26, 2026 [1] Core Insights - The report emphasizes the importance of supply-side variables, particularly the operating rates of raw material drugs, and highlights the potential for price recovery in the antibiotic market due to changes in competition and supply dynamics [2] - Multi-departmental policy support is enhancing the value positioning of pharmacies, transforming them from mere sales points to comprehensive health service platforms [3] - The trend of Chinese innovative drugs going global is gaining momentum, with significant licensing deals and the need for continuous clinical data validation to support long-term investment confidence [4] - Major companies are increasingly investing in the small nucleic acid field, which is expected to accelerate the development of the supporting industrial chain [5] - A new pricing system for GLP-1 drugs is forming in China, with expectations for market growth driven by a large patient population [6] - The report highlights the market value of oral autoimmune drugs, with promising clinical trial results for new treatments [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.23 percentage points in the last week, ranking 27th among 31 sectors [20] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector index increased by 4.98% over the past month, outperforming the CSI 300 index by 3.21 percentage points [37] - The current PE (TTM) for the pharmaceutical sector is 38.51, above the five-year historical average of 31.06 [43] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of the blood products industry and the impact of policies on inhalation formulations [45] 4. Recent Industry Policies and News - Recent policies include the approval of numerous medical device registrations and the promotion of high-quality development in the pharmaceutical retail sector [46][48]

在这一年的交易热潮中，跨国巨头们的采购风格各有不同。谁出手频次最高？谁手笔最大？经济观 察报分析了全年150多笔交易，复盘跨国药企的投资画像与交易特色。 多位受访者对经济观察报表示，其所在药企与潜在合作方达成了进一步沟通意向，他们判断2026 年中国创新药对外授权交易热仍会持续。 2025年爆发式增长的对外授权交易验证了中国创新药资产的价值，该年对外授权总交易额超1300 亿美元，交易数超150笔（约占全球40%），创下历史新高。 阿斯利康最活跃 在交易频次上，阿斯利康是最活跃的跨国药企，2025年一共出手了5次。 合作方包括石药集团（01093.HK）、和铂医药（02142.HK）、加科思药业（01167.HK）、元 思生肽等。其中，在2025年6月与石药集团达成的潜在总交易额超53亿美元的合作，可排进年度 交易额前四。在资产选择上，阿斯利康主要集中在临床早期管线，以及技术平台合作。 在交易频次上，阿斯利康是最活跃的跨国药企，2025年一共 出手了5次。从立即兑现的首付款看，辉瑞与武田制药出手最 阔绰。 作者：张英 封图：图虫创意 作为中国市场销售额最高的外资药企，在经历2024年的公司治理风暴后，阿斯利康 ...

Core Insights - The 2026 JPMorgan Healthcare Conference highlighted significant interest from multinational companies in Chinese assets, particularly in the innovative drug sector [1][2] Group 1: Market Trends - The trend of foreign licensing deals for Chinese innovative drugs is expected to continue in 2026, following a record-breaking year in 2025 where the total licensing deal value exceeded $130 billion, accounting for approximately 40% of global transactions [3] - The surge in licensing deals in 2025 validated the value of Chinese innovative drug assets, with over 150 transactions recorded [3] Group 2: Key Players - AstraZeneca emerged as the most active multinational company in 2025, engaging in five transactions, including a notable deal with CSPC Pharmaceutical Group valued at over $5.3 billion [4] - Pfizer and Eli Lilly each conducted four transactions, with Pfizer's deal with 3SBio setting a record for upfront payments in Chinese innovative drugs at $1.25 billion [5] - GSK's collaboration with Heng Rui Medicine reached a potential total of $12.5 billion, marking the highest deal value for Chinese innovative drugs [13] Group 3: Emerging Markets - Interest in Chinese innovative drugs is not limited to Western companies; firms from India, Latin America, and the Middle East are also engaging in licensing deals [7] - Indian companies Glenmark and Dr. Reddy's each completed two business development transactions in 2025, with Glenmark's deals totaling over $2 billion [8][9] Group 4: Financial Highlights - Three companies, AstraZeneca, GSK, and Takeda, signed contracts exceeding $10 billion, while Pfizer and Novartis secured contracts over $5 billion [10] - The largest single transaction was GSK's deal with Heng Rui Medicine, which included rights to one core drug and options for 11 additional projects [13] Group 5: Future Outlook - Executives at the 2026 JPM conference expressed that Chinese assets are an effective way to supplement pipelines, indicating a shift towards acquiring entire biotechnology platforms rather than just single products [14]

Core Insights - The 2026 JPMorgan Healthcare Conference has highlighted significant trends in the biopharmaceutical industry, particularly in mergers and acquisitions (M&A) among multinational corporations (MNCs) [1] - Major acquisitions include Boston Scientific's $14.5 billion purchase of Penumbra and GSK's $2.2 billion acquisition of RAPT Therapeutics, indicating a strong demand for innovative assets [1][6] - The industry is experiencing a "survival of the fittest" phase, with many biotech firms facing operational challenges and some shutting down due to clinical trial failures [2][8] Mergers and Acquisitions - Boston Scientific has announced two major acquisitions: Valencia Technologies Corporation and Penumbra, with the latter being its largest acquisition in nearly 20 years [1][4] - GSK's acquisition of RAPT Therapeutics aims to leverage its global R&D capabilities to enhance the value of RAPT's pipeline [1][6] - The trend of M&A is driven by MNCs facing a "patent cliff," with an estimated $400 billion in revenue at risk over the next decade [4] Industry Dynamics - The demand for high-quality innovative assets is increasing, leading to a surge in business development (BD) and M&A activities in the biopharmaceutical sector [2][4] - The competitive landscape is shifting from product-based competition to pipeline and product integration capabilities among large pharmaceutical companies [7] - Biotech firms are increasingly viewed as valuable partners for MNCs, providing pathways for pipeline realization and cash flow enhancement [2][10] Challenges for Biotech - Nido Biosciences has ceased operations due to clinical trial failures, highlighting the risks faced by biotech companies in the current environment [2][8] - Financial instability and clinical setbacks are common reasons for biotech firms shutting down, with many struggling to secure funding [8][9] - The industry is witnessing a trend where companies must optimize their pipelines and manage resources effectively to survive [9][10] Future Outlook - The biopharmaceutical sector is expected to see continued M&A activity, particularly focusing on late-stage, lower-risk assets as uncertainties in key policies diminish [4] - Chinese biotech firms are increasingly engaging in BD collaborations with MNCs, driven by cost control and R&D efficiency advantages [10][12] - The industry is at a pivotal point, transitioning from quantity-driven growth to a focus on quality and value creation in the global health landscape [12]

Core Viewpoint - AstraZeneca plans to delist its American Depositary Receipts (ADRs) and debt securities from Nasdaq and list them on the New York Stock Exchange (NYSE), effective after market close on January 30, 2026 [1] Group 1 - The transition from Nasdaq to NYSE is a strategic move by AstraZeneca [1] - The announcement was made on January 20 [1]

Policy Developments - The State Administration for Market Regulation has approved the national standard for "Classification and Determination of Traditional Chinese Medicine Constitution," which will be implemented from April 1. This standard categorizes nine basic types of TCM constitution and aims to enhance health literacy and optimize health service models [2]. Medical Device Approvals - Opcon Vision's application for the registration of "soft hydrophilic contact lenses" has been accepted by the National Medical Products Administration, currently in the acceptance phase [4]. - Livzon Pharmaceutical announced that its clinical trial application for injectable brexpiprazole microspheres for treating schizophrenia has been accepted by the National Medical Products Administration [5]. Capital Markets - AstraZeneca will acquire the remaining 50% equity of Westman Biotech's GPC3 armored CAR-T therapy in China, with a potential payment of up to $630 million, including upfront and milestone payments [7]. - Aote Biological's controlling shareholder has proposed a share buyback plan using funds from its IPO, with a total amount between RMB 100 million and RMB 200 million [8]. Industry Developments - Alibaba Health has launched its self-developed AI medical model "Hydrogen Ion," which is now in practical application, targeting clinical and research fields. This move complements Alibaba's existing health service strategies [10][11]. - Jiangzhong Pharmaceutical has changed its name to "China Resources Jiangzhong Pharmaceutical Co., Ltd." and will also change its stock abbreviation to "China Resources Jiangzhong," while keeping the stock code unchanged [12]. Shareholder Actions - Liaoning He Eye Hospital Group has received a notice from a major shareholder planning to reduce its stake by up to 3,106,074 shares, representing 1.97% of the total share capital, between February 7 and May 6, 2026 [14].